672 related articles for article (PubMed ID: 30053090)
1. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
[TBL] [Abstract][Full Text] [Related]
2. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
Liu G; Wang P; Zhang H
J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
[TBL] [Abstract][Full Text] [Related]
3. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT.
Nie J; Jiang HC; Zhou YC; Jiang B; He WJ; Wang YF; Dong J
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1062-1071. PubMed ID: 30950326
[TBL] [Abstract][Full Text] [Related]
4. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
5. A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer.
Sun J; Li X; Yu E; Liu J; Sun L; He Q; Lu Q
Diagn Pathol; 2021 May; 16(1):45. PubMed ID: 34006305
[TBL] [Abstract][Full Text] [Related]
6. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo.
Mohammadi-Yeganeh S; Hosseini V; Paryan M
J Cell Physiol; 2019 Aug; 234(10):18317-18328. PubMed ID: 30945294
[TBL] [Abstract][Full Text] [Related]
7. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
8. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-124-3p.1 promotes cell proliferation through Axin1-dependent Wnt signaling pathway and predicts a poor prognosis of triple-negative breast cancer.
Yang W; Cui G; Ding M; Yang M; Dai D
J Clin Lab Anal; 2020 Jul; 34(7):e23266. PubMed ID: 32125723
[TBL] [Abstract][Full Text] [Related]
11. Sesamol inhibits proliferation, migration and invasion of triple negative breast cancer via inactivating Wnt/β-catenin signaling.
Ma X; Hu X; Zhu Y; Jin H; Hu G; Ding L; Ning S
Biochem Pharmacol; 2022 Dec; 206():115299. PubMed ID: 36244446
[TBL] [Abstract][Full Text] [Related]
12. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
13. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
14. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
[TBL] [Abstract][Full Text] [Related]
16. HePTP promotes migration and invasion in triple-negative breast cancer cells via activation of Wnt/β-catenin signaling.
Yu L; Wang C; Pan F; Liu Y; Ren X; Zeng H; Shi Y
Biomed Pharmacother; 2019 Oct; 118():109361. PubMed ID: 31545274
[TBL] [Abstract][Full Text] [Related]
17. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
18. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.
Wang L; Kang FB; Wang J; Yang C; He DW
Anticancer Drugs; 2019 Mar; 30(3):225-232. PubMed ID: 30334817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
